Search results for "CARDIOVASCULAR DISEASE."

showing 10 items of 2331 documents

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

Electrocardiography for Assessment of Hypertensive Heart Disease: A New Role for an Old Tool

2016

Left ventricular (LV) hypertrophy (LVH), detected either by electrocardiography (ECG) or echocardiography (ECHO), has long been recognized as a powerful predictor of serious cardiovascular (CV) sequelae. A very large and highly consistent body of evidence indicates that LVH is not only an adaptation to increased hemodynamic load in hypertension, but is also independently associated with an enhanced risk for myocardial infarction, cardiac sudden death, congestive heart failure, and stroke in the general population, as well as in patients with systemic hypertension, coronary heart disease, chronic kidney disease, and atrial fibrillation. Intriguingly, the cumulative incidence of cardiovascula…

medicine.medical_specialtySettore MED/09 - Medicina InternaCardiology and Cardiovascular Medicine; Internal Medicine; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismPopulation030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineMedicinecardiovascular diseases030212 general & internal medicineMyocardial infarctioneducationSettore MED/14 - Nefrologiaeducation.field_of_studymedicine.diagnostic_testbusiness.industryAtrial fibrillationmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureHeart failureCardiologyPhysical therapyCardiology and Cardiovascular MedicinebusinessElectrocardiography
researchProduct

Obesity and cardiovascular risk: the new public health problem of worldwide proportions

2004

Obesity could be considered a new global health epidemic above all others, especially when it is characterized by central fat distribution. This is illustrated by dramatic provisional data, indicating a continuous increase in the trend of overweight and obese individuals in several countries, including the USA and countries in Europe. Several epidemiological, pathophysiological and clinical studies clearly indicate that two of the major independent risk factors for cardiovascular disease or events are being overweight, and obesity. Accordingly, weight loss and prevention of weight gain has to be considered one of the most important strategies to reduce the incidence of cardiovascular diseas…

medicine.medical_specialtySettore MED/09 - Medicina InternaCoronary DiseaseHyperlipidemiasDiseaseOverweightGlobal HealthBody Mass IndexRisk FactorsWeight lossEnvironmental healthEpidemiologyInternal MedicinemedicineGlobal healthHumansObesityHeart Failurecardiovascular risk heart failure hypertension ischemic heart disease obesitybusiness.industryPublic healthGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityUnited StatesEuropeCardiovascular DiseasesHypertensionPhysical therapyAnti-Obesity Agentsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexExpert Review of Cardiovascular Therapy
researchProduct

Clinical utility of novel biomarkers for cardiovascular disease risk stratification

2012

Over the past few decades, a number of coronary artery disease (CAD) and cardiovascular disease (CVD) risk factors have been identified. The predictive power of "conventional" risk factors have been validated by observational, prospective and intervention studies. Nevertheless, all attempts to exactly predict the individual risk for CAD have failed, biased by a large number of incorrectly risk-classified subjects. To improve cardiovascular (CV) risk prediction, a large number of genetic and/or non-genetic biomarkers have been discovered and tested against the "classical" risk factors for their power to predict CV risk. Only few of them had a significant improvement over the predictive model…

medicine.medical_specialtySettore MED/09 - Medicina InternaDiseaseIndividual riskRisk AssessmentCoronary artery diseaseInternal MedicinemedicineHumansRisk factorIntensive care medicinebusiness.industryBiomarkerCardiovascular riskAtherosclerosismedicine.diseaseIntervention studiesSurgeryCardiovascular DiseasesEmergency MedicineDisease riskPredictive powerObservational studybusinessPredictive powerBiomarkersInternal and Emergency Medicine
researchProduct

A novel component of the metabolic syndrome: The oxidative stress

2009

The metabolic syndrome (MS) represents a cluster of cardiovascular (CV) risk factors associated to CV disease and type 2 diabetes. It is still under debate whether MS is a mere aggregation of risk factors or it represents a clinical entity with visceral obesity as underlying pathophysiological trigger. The publication of several diagnostic criteria of MS by scientific associations or experts panels reflects this uncertainty in understanding the real nature of MS. Besides the metabolic disturbances of MS, as visceral obesity, hypertriglyceridemia, low HDL cholesterol, hypertension and hyperglycemia, novel mechanisms of arterial damage have been identified. This paper reviews the evidence sho…

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Blood lipidsType 2 diabetesDiseaseBiologyBioinformaticsmedicine.disease_causeRisk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumansDyslipidemiasInflammationMetabolic SyndromeNutrition and DieteticsHypertriglyceridemiaCardiovascular riskmedicine.diseaseObesityOxidative StressEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesObesity AbdominalHypertensionMetabolic syndromeCardiology and Cardiovascular MedicineOxidative stressNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Heart involvement in rheumatoid arthritis: systematic review and meta-analysis.

2013

Abstract Objective The aim of our study was to conduct a systematic review with meta-analysis of the current case–control studies about the valvular and pericardial involvement in patients with Rheumatoid Arthritis (RA), asymptomatic for cardiovascular diseases. Methods Case–control studies were identified by searching PubMed (1975–2010) and the Cochrane Central Register of Controlled Trials (CENTRAL) (1975–2010). Participants were adult patients with RA asymptomatic for cardiovascular diseases, and the outcome measure was the presence of cardiac involvement. Results Quantitative synthesis included 10 relevant studies out of 2326 bibliographic citations that had been found. RA resulted sign…

medicine.medical_specialtySettore MED/09 - Medicina InternaHeart Valve DiseasesPericardial effusionAsymptomaticArthritis RheumatoidInternal medicineMitral valvemedicineMitral valve prolapseHumansbusiness.industrymedicine.diseaseRheumatoid Arthritis Systematic review Meta-analysis Echocardiography assessment Pericardial disease Cardiac valvular calcificationSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatrichemedicine.anatomical_structureCardiovascular DiseasesEchocardiographyAortic valve stenosisRheumatoid arthritisMeta-analysisCase-Control StudiesCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessCalcificationInternational journal of cardiology
researchProduct

Antiplatelets in stroke prevention

2014

Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic st…

medicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINEPrimary preventionSecondary PreventionmedicineAnimalsHumanscardiovascular diseasesMyocardial infarctionIntensive care medicineStrokeCause of deathPharmacologySecondary preventionAspirinAspirinbusiness.industrymedicine.diseasePrimary PreventionStrokeCardiovascular DiseasesPhysical therapyPlatelet aggregation inhibitorantiplatelets Stroke preventionCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Magnesium and hypertension in old age

2021

Hypertension is a complex condition in which various actors and mechanisms combine, resulting in cardiovascular and cerebrovascular complications that today represent the most frequent causes of mortality, morbidity, disability, and health expenses worldwide. In the last decades, there has been an exceptional amount of experimental, epidemiological, and clinical studies confirming a close relationship between magnesium deficit and high blood pressure. Multiple mechanisms may help to explain the bulk of evidence supporting a protective effect of magnesium against hypertension and its complications. Hypertension increases sharply with advancing age, hence older persons are those most affected…

medicine.medical_specialtySettore MED/09 - Medicina InternaMagnesium supplementationchemistry.chemical_elementBlood Pressurelcsh:TX341-641Review030204 cardiovascular system & hematologyHypertension riskAging Cardiovascular disease03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseMagnesium deficiency (medicine)EpidemiologymedicineHumansMagnesium030212 general & internal medicineMicronutrientsIonIntensive care medicineAgedAged 80 and overNutrition and Dieteticsbusiness.industryMagnesiumagingInsulin resistanceFeeding Behaviormedicine.diseaseDietBlood pressurechemistryClose relationshipDietary SupplementsHypertensionionsbusinessMagnesium Deficiencylcsh:Nutrition. Foods and food supplyFood ScienceSupplement
researchProduct

Matrix metalloproteinases in metabolic syndrome.

2011

Metabolic syndrome is commonly accompanied by an elevated cardiovascular risk with high morbidity and mortality. The alterations of the arterial vasculature begin with endothelial dysfunction and lead to micro- and macrovascular complications. The remodeling of the endothelial basal membrane, that promotes erosion and thrombosis, has a multifactorial pathogenesis that includes leukocyte activation, increased oxidative stress and also an altered matrix metalloproteinases (MMPs) expression. MMPs are endopeptidases which degrade extracellular matrix proteins, such as collagen, gelatins, fibronectin and laminin. They can be secreted by several cells within the vascular wall, but macrophages are…

medicine.medical_specialtySettore MED/09 - Medicina InternaMatrix metalloproteinaseGlobal HealthPathogenesisExtracellular matrixRisk FactorsDiabetes mellitusInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctionMetabolic Syndromebiologybusiness.industryMETABOLIC SYNDROME MATRIX METALLOPROTEASES CARDIOVASCULAR RISKmedicine.diseaseMatrix MetalloproteinasesSurvival RateFibronectinOxidative StressEndocrinologyCardiovascular Diseasesbiology.proteinMorbidityMetabolic syndromebusinessDyslipidemia
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct